PT Kalbe Farma Tbk (KLBF) recorded a net profit of Rp924, 150 billion during the first half of 2013. The net income growth from the previous year amounting to Rp807, 832 billion.
Quoted from financial reports, on Wednesday (07/31/2013), basic earnings per share of pharmaceutical and healthcare products company that was increased to Rp20 per share from the previous year Rp17 per share.
The increase was driven by sales of products that make the company’s revenue of Rp 7, 421 billion in the period January to June 2013. The revenue growth over the previous year of Rp 6, 243 trillion.
The Company also recorded a gross profit in the January-June 2013 amounted to Rp3, 622 trillion, up from the previous year amounting to Rp3, 063 trillion.
Income before income tax expense was also recorded at Rp1, 22 trillion increase over the previous year amounting to Rp1, 08 trillion.
Erajaya Swasembada Tbk PT (ERAA), a listed retail distributor of mobile phones, reported a net profit in the first half of 2013 fell 39.9 percent from the same period a year earlier. Net income fell from Rp 212.4 billion in Semester 1 2012 to Rp 129.8 billion in Semester 1 2013.
Djatmiko Ward, Director of Marketing and Communications Erajaya, said the decline in net income was due to the decreased net sales of Rp 6.4 trillion to Rp 5.9 trillion in the first semester of 2013. Sales decreased due to sales of mobile phones fell from 5.2 million to 4.9 million in the first half of 2013.
“Sales of mobile phones and tablets from the company recorded 88.1 percent of net sales, sales fell to Rp 5.2 trillion from net sales of Rp 5.9 trillion in the first half of 2012, net income decreased as a result,” he said in Jakarta on Wednesday (31/07/2013).
This gives the effect of the sale of product sales boom era. So kontribursi such as through vouchers, computers and electronics segment, as well as accessories segment is not able to increase the company’s revenue.
Vouchers 489.6 billion recorded in the first half of 2013 up from 397.6 billion in the first half of 2012. While computers and computer equipment segment recorded sales of 129.6 billion in the first half of 2013. And accessories segment recorded an increase of 89.7 billion from the 1st half of 2012 amounted to 12.5 billion.
A result of the drop in sales was also lower pre-tax profit (EBITDA) of the company on the 1st half of 2013 were down 37.2 percent to Rp 180.5 billion in EBITDA than in the 1st half 2013 that reached Rp 287.1 billion.
PT Kalbe Farma, drug manufacturers and national health supplements, plans to build a dairy factory in the Cikampek, West Java. According to the Director of Finance and Corporate Secretary of Kalbe Farma, Vidjongtius, the plant cost around Rp 300 billion. “The project started in 2014,” he said at a media gathering.
Vidjongtius said the plant will be owned by the installation of a fourth milk production Kalbe Farma. With the construction of this plant, Kalbe increase milk production capacity of 12 thousand tons to 24 thousand tons per year.
Funds to build the plant will be met from capital expenditure Kalbe Farma in 2013, which reached Rp 1.5 trillion. According Vidjongtius, until the first half, the company has spent at least 40 percent of the annual capital expenditure. “The new plant is expected to support business growth in the future,” he said.
In 2012, Kalbe has completed the construction of dairy factory in Sukabumi, West Java. This plant is the result of cooperation with PT Milko Beverage Industry. Kalbe, which poured an investment of Rp 154 billion, became the majority owner with 51 percent parts.
Throughout 2013, Kalbe targeting revenue growth and net income by 18 percent. That figure is above the growth of the pharmaceutical industry which reached 15 percent. In 2012, Kalbe Farma pocketed a net profit of Rp 1.73 trillion and Rp 13.6 trillion in net sales. Thus, the company targets a net profit of Rp 2.04 trillion and Rp 16 trillion in net sales in 2013.